More on MDGL
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $447.09 |
|
|||
| Open | $447.09 | ||||
| 52 Wk High | $18.24 | ||||
| 52 Wk Low | $6.60 | ||||
| Day High | $447.09 | ||||
| Day Low | $447.09 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1 | ||||
- Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Pharmaceuticals (MDGL) PT Raised to $735 at UBS
- Madrigal publishes Rezdiffra genetic subgroup data in liver journal
- Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
- Goldman Sachs Assumes Madrigal Pharmaceuticals (MDGL) at Buy
- Citi initiates Madrigal Pharmaceuticals coverage with Buy rating
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Pharmaceuticals adds J&J executive to its board
Entities mentioned with MDGL
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Goldman Sachs | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S3 | View Related Stories »
- Show More...
